Last reviewed · How we verify
Netarsudil Ophthalmic
Netarsudil is a Rho kinase inhibitor and norepinephrine transporter antagonist that reduces intraocular pressure by increasing conventional outflow and decreasing episcleral venous pressure.
Netarsudil is a Rho kinase inhibitor and norepinephrine transporter antagonist that reduces intraocular pressure by increasing conventional outflow and decreasing episcleral venous pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Netarsudil Ophthalmic |
|---|---|
| Also known as | Latanoprost Ophthalmic, Rhopressa, Rhopressa® |
| Sponsor | University of the Incarnate Word |
| Drug class | Rho kinase inhibitor |
| Target | ROCK1/ROCK2, norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Netarsudil works through dual mechanisms: it inhibits Rho-associated protein kinase (ROCK), which increases trabecular meshwork outflow facility and reduces episcleral venous pressure, and it blocks the norepinephrine transporter, which decreases aqueous humor production. These combined effects result in significant intraocular pressure reduction in glaucoma and ocular hypertension patients.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Corneal verticillata
- Eye pain or discomfort
- Blurred vision
- Conjunctival hemorrhage
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Next Generation Rocklatan (PHASE2)
- Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |